back to homepage

Session 27

Challenges for validation of predictive biomarkers for both toxicology and ecotoxicology

Programme of the Session

  • S27-01
    Common good practices in biomarker development in toxicology and ecotoxicology

    Fiorella Belpoggi1, Lygia Therese Budnik2
    1Ramazzini Institute, Cesare Maltoni Cancer Research Center, Bentivoglio, Bologna, Italy; 2University Medical Center Hamburg-Eppendorf, Institute for Occupational and Maritime Medicine, Translational Toxicology and Immunology, Hamburg, Germany
  • S27-02
    Role of the adverse outcome pathway (AOP) framework in the validation of predictive biomarkers 

    Daniel Villeneuve
    US Environmental Protection Agency, Office of Research and Development, Mid-Continent Ecology Division, Duluth, United States
  • S27-03
    Biomarkers in invertebrate species: addressing environmental, physiological and phylogenetic variability for a reliable monitoring of freshwater ecosystem contamination 

    Olivier Geffard, Arnaud Chaumot  

    Ecotoxicology, Irstea, Villeurbanne, France

  • S27-04
    Pathway analysis of neurodevelopment toxicity due to prenatal combined exposure to heavy metals and phthalates

    Denis A. Sarigiannis1,2,3*, Kinga Polanska4, Woijcek Hanke4, Athanasios Salifoglou1, Aikaterini Gabriel1, Nafsika Papaioannou1, Evangelos Handakas2, Spyros Karakitsios1,2

    1HERACLES Research Center – KEDEK, Aristotle University of Thessaloniki, Greece; 2Environmental Engineering Laboratory, Department of Chemical Engineering, Aristotle University of Thessaloniki, Greece; 3 Environmental Health Engineering, School for Advanced Study IUSS, Pavia, Italy; 4Nofer Institute of Occupational Medicine, 91348, Lodz, Poland

Session Abstract

The idea of the workshop is to share expertise and practices between toxicology and ecotoxicology for the validation of predictive biomarkers. The idea is to go further classical regulatory requirements in order to ensure that a defined biomarker is biologically plausible, that there is a threshold between a normal status and adverse effect at different scales (from molecule to population), that short as well as long-term effects are related to the temporality of the exposure during life time, that genomic, epigenomic and phenotypic status of an organism or a population and related effects is taken into account during the exposure leading to an adverse effect.
The work shop aims to propose “good practices” in biomarker designed in order to fulfil the different criteria that make it biologically plausible beyond regulatory requirements.

© 2016–2017 GUARANT International